1. High takeover premiums – Biotech takeovers typically feature significant control premiums. Since 2020, the average biotech takeover premium was 87.5%, compared to the M&A universe average (ex-biotech) of 41.7%. In addition, takeover over premiums in the biotech sector can soar to truly astronomical levels, with seven deals featuring a takeover premium above 200%, two north of 300%, and one at a stunning 667% premium. Large takeover premiums are extremely rewarding to investors.
As PAA has a First in Class Medicine with multiple known targets and Clinical data in Oncology and Covid , HVTL-1 etc we should be asking a swerious premium , plus our Tablet cost is low , $1.50 to $2.00 a Tablet ,, Huge margins here NZT
Company presenting at Techknow in Sydney (today)/ Melbourne (tomorrow), page-32
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.015(7.89%) |
Mkt cap ! $99.76M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.5¢ | 19.5¢ | $129.6K | 653.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 119947 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 119150 | 7 |
View Market Depth
| Last trade - 15.59pm 09/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |